The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques
Introduction
Locoregional breast cancer recurrence occurs in about 10% of all breast cancer patients,1 with a 5-year survival rate of approximately 60%.2 Curative local treatment remains an option if the recurrence is truly locoregional. Even patients with locally advanced breast cancer recurrences can be treated with lasting local control, provided that there are no distant metastases.3 Therefore, adequate and accurate staging of the recurrence is imperative for optimal treatment of these patients.
At the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/AVL) conventional staging procedures in patients with locoregional breast cancer recurrence generally consists of physical examination to evaluate the local-regional situation, magnetic resonance imaging-scan (MRI) for local-regional evaluation and a chest radiograph, liver ultrasound or computed tomography (CT) scan and a bone scan, to diagnose potential distant metastases. With these conventional imaging techniques, approximately 10% of the patients will show overt distant metastases at the time of diagnosis of the locoregional breast cancer recurrence.4, 5 However, the performance of this diagnostic strategy appears to be suboptimal since approximately 40% of patients will be diagnosed with distant metastases within 5 years.2, 5, 6, 7
18F-fluorodeoxyglucose positron-emission tomography (FDG PET) was found to be a sensitive modality in the assessment of breast cancer recurrence with a sensitivity ranging from 89 to 100%.8, 9, 10, 11 Unfortunately the lack of anatomic information of FDG PET alone may affect its specificity.12, 13 The recently introduced integrated PET/CT can provide both morphologic and metabolic information, by combining anatomic CT data and functional FDG PET data. Since FDG PET/CT is not organ specific and provides a whole-body overview, it can potentially replace the array of conventional imaging.
This retrospective study evaluates the diagnostic performance of FDG PET/CT, compared to conventional imaging techniques, and evaluates the impact of these results on clinical management of patients with a confirmed locoregional breast cancer recurrence.
Section snippets
Patients
From January 2006 until August 2008, 56 patients underwent total body FDG PET/CT imaging because of a confirmed locoregional breast cancer recurrence at the NKI-AVL. All recurrences were confirmed by fine needle aspiration or core needle biopsy. Because extensive locoregional surgery was deemed necessary, patients were referred to visualise the extent of the recurrence and to exclude metastatic disease. The patient's age and tumour stage at primary diagnosis of breast carcinoma, the initial
Patient characteristics
The median age at the time of primary breast carcinoma was 48 years (range 27–74). The median time to recurrence was 4.0 years (range 0.4–17.8 years). The characteristics of the original primary tumours and the initial treatments are summarized in Table 1.
Conventional imaging
Besides FDG PET/CT imaging, 21 patients underwent MRI of the chest, 32 patients underwent chest radiography, 20 patients underwent a diagnostic CT of the chest, 35 patients underwent bone scintigraphy and 30 patients underwent ultrasound of
Discussion
Patients with locoregional breast cancer recurrence can be treated adequately with surgery. The clinical management and prognosis of these patients are mainly based on the extent of the locoregional recurrence and the presence of distant metastases.2, 3, 14, 15 Therefore, accurate staging is essential for surgical treatment of patients with a locoregional recurrence.
The sensitivity of conventional imaging techniques for the detection of distant metastases in breast cancer patients ranges from
Conflict of interest statement
The authors declare no conflict of interest.
References (29)
- et al.
Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC breast cancer cooperative group and the Danish Breast Cancer Cooperative Group
Eur J Cancer
(1999) - et al.
Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity
Eur J Surg Oncol
(2009) - et al.
Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography
Eur J Cancer
(2004) - et al.
Prognosis following local recurrence in the conservatively treated breast cancer patient
Int J Radiat Oncol Biol Phys
(1991) - et al.
Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis
Int J Radiat Oncol Biol Phys
(1992) - et al.
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer
Ann Oncol
(2008) - et al.
The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast
Semin Nucl Med
(2006) - et al.
The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer
Clin Positron Imaging
(2000) - et al.
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases
Ann Oncol
(2007) - et al.
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials
J Clin Oncol
(2001)